ArticleBMC psychiatry2017
Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine.
Article in BMC psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 72 citations in OpenAlex.
- Patients' experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study.Addiction science & clinical practice · 2022Trial
- Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse.Addiction (Abingdon, England) · 2022Trial
- "I still can feel the sickness": Withdrawal experiences of people on methadone maintenance treatment.Journal of substance use and addiction treatment · 2025Article
- Opioid Coprescription Through Risk Mitigation Guidance and Opioid Agonist Treatment Receipt.JAMA network open · 2024Article
- Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT).Substance abuse treatment, prevention, and policy · 2024Article
- Substance use patterns and negative urine opioid screen among patients on methadone treatment at a referral hospital in Nairobi, Kenya.PLOS mental health · 2024Article
- The association of medical providers' attitudes about naloxone and people with opioid use disorder and their self-reported "low-barrier" treatment practices.Addictive behaviors reports · 2023Article
- Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder.Drug and alcohol dependence · 2022Article
- Rationale, design, and methodology of a randomized pilot trial of an integrated intervention combining computerized behavioral therapy and recovery coaching for people with opioid use disorder: The OVERCOME study.Contemporary clinical trials communications · 2022Article
- Addressing injecting related risks among people who inject both opioids and stimulants: Findings from an Australian survey of people who inject drugs.Addictive behaviors reports · 2022Article
- Initiation of opioid agonist treatment and subsequent substance use and other patterns among adolescents and young adults in Vancouver, Canada.Drug and alcohol dependence · 2022Article
- Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.JAMA network open · 2022Observational
- The prevalence and pattern of cannabis use among patients attending a methadone treatment clinic in Nairobi, Kenya.Substance abuse treatment, prevention, and policy · 2022Article
- Effects of buprenorphine/lorcaserin mixtures on preference for heroin, cocaine, or saline over food using a concurrent choice procedure in rhesus monkeys.Drug and alcohol dependence · 2021Article
- Cannabis use in patients treated for opioid use disorder pre- and post-recreational cannabis legalization in Canada.Substance abuse treatment, prevention, and policy · 2021Article
- High prevalence of co-occurring substance use in individuals with opioid use disorder.Addictive behaviors · 2021Article
- Global opioid agonist treatment: a review of clinical practices by country.Addiction (Abingdon, England) · 2020Review
- Patterns, contexts, and motivations for polysubstance use among people who inject drugs in non-urban settings in the U.S. Northeast.The International journal on drug policy · 2020Article
- A qualitative study of diphenhydramine injection in Kyrgyz prisons and implications for harm reduction.Harm reduction journal · 2020Article
- Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting.Drug and alcohol dependence · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolydrug abuse is a known problem among opioid-dependent patients receiving opioid maintenance treatment (OMT). However, improved laboratory diagnostics is required to reveal polydrug abuse in its current scope. Furthermore, there are few studies focusing on the relationship between polydrug abuse and adequacy of the dose of OMT medicine. This study aimed to evaluate the polydrug abuse among opioid-dependent patients receiving OMT with inadequate (Group IA) and adequate (Group A) doses of OMT medicine as experienced by the patients. Craving for opioids and withdrawal symptoms were evaluated as indicators of the adequacy rating.
methodsThis is a retrospective register-based study of 60 OMT patients on either methadone or sublingual buprenorphine/naloxone medication, whose polydrug abuse was studied from urine samples by means of a comprehensive high-resolution mass spectrometry method.
resultsInadequate doses of the OMT medicines were associated with higher subjective withdrawal scores and craving for opioids. Six groups of abused substances (benzodiazepines, amphetamines, opioids, cannabis, new psychoactive substances, and non-prescribed psychotropic medicines) were found among OMT patients. Group IA patients showed significantly more abuse of benzodiazepines and amphetamines than the Group A patients. All the new psychoactive substances and most of the non-prescribed psychotropic medicines were detected from the Group IA patients. There was no difference in the doses of the OMT medicine between Groups IA and A patients.
conclusionsPolydrug abuse, detected by definitive laboratory methods, was widespread and more common among Group IA than Group A patients, emphasizing the requirement for individual OMT medicine dose adjustment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.